BIO-MH-Early Biomarkers in Premanifest Huntington's Disease Gene Carriers

Recruiting

LEARN MORE

SPONSOR

University Hospital, Grenoble

PARTICIPANTS

20

The primary objective of this study is to investigate the function of SC in response to visual stimulation using a funcional MRI(fMRI) in premanifest HD gene carriers (PMGC) compared to healthy subjects (HS). Our main hypothesis is the dysfunction of the SC at the pre-symptomatic stage of the disease (role of SC as an early biomarker of the disease). The superior colliculus (SC) is a midbrain structure involved in the integration of visual stimuli, in the generation of oriented eye movements and attention tasks.

Secondary objectives will be:

  1. To study gait parameters using 3D virtual reality equipment in PMGC compared to HC, to demonstrate that they are abnormal at the pre-symptomatic stage of the disease.
  2. To investigate the cognitive/emotional behavior in PMGC compared to HC, to demonstrate that it is abnormal at the pre-symptomatic stage of the disease.
  3. To study the correlation between gait, neuroimaging, cognitive/emotional data and various clinical and neuropsychological variables.
  4. To investigate potential pre-symptomatic subtypes profiles in HD carriers, based on neuroimaging, clinical, cognitive/emotional assessments correlation analysis.

 

Ages Eligible
for Study:

18 Years to 70 Years (Adult,  Older Adult )

Sexes Eligible
for Study:

All

Accepts Healthy Volunteers:

Yes

  • 1. For presymptomatic genetic carriers of Huntington(PMGC): HD diagnosis confirmed by genetic testing (CAG triplets ≥36 in HTT gene); Unified Huntington Disease Rating Scale19 Total Motor Score (UHDRS-TMS) ≤ 5; age 18-70 years old. 2.
  • For Healthy Controls(HC): normal neurological examination; age 18-70 years old.
  • Main exclusion criteria for both PMGC and HC will be: major ophthalmologic and psychiatric active diseases; cognitive impairment (Montreal Cognitive Assessment, MoCA score < 25/30); gait issues related to non-neurological conditions; contraindications to brain MRI.

LOCATIONS

FRANCE

TRIAL SITE:
Grenoble University Hospital 

Address: Grenoble,  France

CONTACT:Sara Meoni, MD, PhD

Email: smeoni@chu-grenoble.fr

Recruiting